# US 2021/0340542 A1 · Rna molecules, methods of producing circular rna, and treatment methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340542 A1
- Document ID: US20210340542A1
- Status: Published application
- Kind: A1
- Application number: 16/625,562
- Filed: 2018-06-23
- Published: 2021-11-04
- Earliest claimed: 2017-10-18
- Assignees: Cornell University
- Applicants: Cornell University
- Inventors: Samie R. JAFFREY; Jacob L. LITKE
- Web page: https://patentgrep.com/patent/US20210340542A1

## CPC

- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- G06T 7/001: {using an image reference approach}
- A61K 31/7115: Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- G01N 21/8851: {Scan or image signal processing specially adapted therefor, e.g. for scan signal adjustment, for detecting different kinds of defects, for compensating for structures, markings, edges (G01N21/8806 and G01N21/93 - G01N21/95692 take precedence; optical measurement of dimensions G01B11/00; optical scanning G02B26/10; image transformation G06T3/00; computerised image enhancement G06T5/00; image processing per se for flaw detection G06T7/0002)}
- G01N 21/9501: {Semiconductor wafers (manufacturing processes per se of semiconductor devices implementing a measuring step H10P74/20)}
- G01N 21/95607: {using a comparative method}
- G06T 7/11: Region-based segmentation
- C12N 2310/128: processing or releasing ribozyme
- C12N 2310/16: Aptamers
- C12N 2310/3519: Fusion with another nucleic acid
- C12N 2310/51: in polymeric form, e.g. multimers, concatemers
- C12N 2310/532: Closed or circular
- C12N 2330/51: Specially adapted vectors
- G01N 2021/95615: {with stored comparision signal}
- G06T 2207/20104: Interactive definition of region of interest [ROI]
- G06T 2207/30148: Semiconductor; IC; Wafer
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G06T: IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a RNA molecule comprising a first ribozyme, a first ligation sequence, an effector molecule, a second ligation sequence, and a second ribozyme. Methods of producing circular RNA molecules and treatment methods are also disclosed.

## Claims

### Claim 1

A RNA molecule comprising:
a first ribozyme;
a first ligation sequence;
an effector molecule;
a second ligation sequence; and
a second ribozyme.

### Claim 2 (depends on 1)

The RNA molecule of claim 1, wherein the RNA molecule comprises a non-natural or modified nucleotide.

### Claim 3 (depends on 1)

The RNA molecule of claim 1, wherein each of the first ribozyme and the second ribozyme comprises a sequence that may be cleaved to produce a 5′-OH end and a 2′,3′-cyclic phosphate end.

### Claim 4 (depends on 3)

The RNA molecule of claim 3, wherein each of the first and the second ribozyme is independently selected from the group consisting of Hammerhead, Hairpin, Hepatitis Delta Virus (“HDV”), Varkud Satellite (“VS”), Vg1, glucosamine-6-phosphate synthase (“glmS”), Twister, Twister Sister, Hatchet, Pistol ribozymes, engineered synthetic ribozymes, or derivatives thereof.

### Claim 5 (depends on 4)

The RNA molecule of claim 4, wherein each of the first and the second ribozyme is, independently, a split ribozyme or ligand-activated ribozyme derivative.

### Claim 6 (depends on 3)

The RNA molecule of claim 3, wherein the first ribozyme is a P3 Twister ribozyme and the second ribozyme is a P1 Twister ribozyme.

### Claim 7 (depends on 1)

The RNA molecule of claim 1, wherein each of the first ligation sequence and the second ligation sequence are substrates for an RNA ligase.

### Claim 8 (depends on 7)

The RNA molecule of claim 7, wherein each of the first ligation sequence and the second ligation sequence comprise a portion of a tRNA exon sequence or derivative thereof.

### Claim 9 (depends on 7, 8)

The RNA molecule of claim 7 or claim 8, where in the RNA ligase is RtcB.

### Claim 10 (depends on 1)

The RNA molecule of claim 1, wherein the effector molecule is selected from the group consisting of a RNA sequence that binds a protein; an RNA sequence that is complementary to a microRNA or siRNA; an RNA sequence that has partial complementarity to a microRNA or siRNA or piRNA; an RNA sequence that hybridizes completely or partially to a cellularly expressed microRNA, siRNA, piRNA, mRNA, lncRNA, ncRNA, or other cellular RNA; a hairpin structure that is a substrate for DICER or endogenous nucleases; a sequence that binds to viral proteins; an antisense RNA, an antagomir, a microRNA, a siRNA, an anti-miRNA, a ribozyme, a decoy oligonucleotide, an RNA activator, an immunostimulatory oligonucleotide, an aptamer, an RNA device; and an RNA molecule encoding a peptide sequence.

### Claim 11 (depends on 10)

The RNA molecule of claim 10, wherein the effector molecule comprises an IRES coupled to an RNA molecule encoding a peptide sequence.

### Claim 12 (depends on 10)

The RNA molecule of claim 10, wherein the effector molecule is a sensor comprising a fluorogenic aptamer coupled to a metabolite binding partner.

### Claim 13 (depends on 12)

The RNA molecule of claim 12, wherein the fluorogenic aptamer is selected from Spinach, Spinach 2, Broccoli, Red-Broccoli, Orange Broccoli, Corn, Mango, Malachite Green, cobalamine-binding aptamer, and derivatives thereof.

### Claim 14 (depends on 13)

The RNA molecule of claim 13, wherein the fluorogenic aptamer binds to a fluorophore whose fluorescence, absorbance, spectral properties, or quenching properties are increased, decreased, or altered by interaction with the fluorogenic aptamer.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The RNA molecule according to any of claims 1-14, wherein the RNA molecule comprises a 5′-OH end.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The RNA molecule according to any of claims 1-14, wherein the RNA molecule comprises a 2′,3′-cyclic phosphate end.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The RNA molecule according to any of claims 1-14, wherein the RNA molecule comprises a 5′-OH end and a 2′,3′-cyclic phosphate end.

### Claim 18 (depends on 17)

The RNA molecule of claim 17, wherein the RNA molecule is a substrate for a RNA ligase.

### Claim 19 (depends on 18)

The RNA molecule of claim 18, wherein the RNA ligase is RtcB.

### Claim 20 (depends on 1)

A circular RNA molecule produced from the RNA molecule of claim 1, wherein the circular molecule comprises the effector molecule.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A vector encoding the RNA molecule of any of claims 1-20.

### Claim 22 (depends on 21)

The vector of claim 21, wherein the vector comprises a promoter operatively coupled to the nucleic acid molecule.

### Claim 23 (depends on 22)

The vector of claim 22, where in the promoter is a prokaryotic promoter selected from the group consisting of T7, T3, SP6 RNA polymerases, and derivatives thereof.

### Claim 24 (depends on 22)

The vector of claim 22, wherein the promoter is a eukaryotic RNA Polymerase II promoter or a derivatives thereof.

### Claim 25 (depends on 22)

The vector of claim 22, wherein the promoter is a eukaryotic RNA polymerase I promoter or RNA Polymerase III promoter selected from the group consisting of U6, H1, 5S, 7SK promoter, and derivatives thereof.

### Claim 26 (depends on 21)

A cell comprising the vector of claim 21.

### Claim 27 (depends on 26)

The cell of claim 26, wherein the cell comprises an endogenous RNA ligase.

### Claim 28 (depends on 27)

The cell of claim 27, wherein the endogenous RNA ligase has the ability to catalyze the circularization of a ribonucleic acid molecule having a 5′-OH and a 2′,3′-cyclic phosphate.

### Claim 29 (depends on 28)

The cell of claim 28, wherein the endogenous RNA ligase is RtcB.

### Claim 30

A method of producing a circular RNA molecule, said method comprising:
providing one or more vectors comprising:
a nucleic acid sequence encoding a 5′ polymerase promoter sequence;
a nucleic acid sequence encoding a first ribozyme;
a nucleic acid sequence encoding an effector sequence;
a nucleic acid sequence encoding a second ribozyme; and
a nucleic acid sequence encoding a 3′ polymerase terminator sequence;
transcribing the one or more vectors to produce one or more linear RNA molecules; and
contacting the linear RNA molecules with an RNA ligase to circularize the linear RNA molecule thereby producing a circular RNA molecule.

### Claim 31 (depends on 30)

The method of claim 30, wherein said transcribing the one or more vectors is carried out by introducing the vector into a cell.

### Claim 32 (depends on 30)

The method of claim 30, wherein the RNA ligase is contained in the cell.

### Claim 33 (depends on 30)

The method of claim 30, wherein the one or more linear RNA molecules comprise a 5′-OH end, a 2′,3′-cyclic phosphate end, and combinations thereof.

### Claim 34 (depends on 30)

The method of claim 30, wherein the RNA ligase is RtcB.

### Claim 35 (depends on 30)

The method of claim 30, wherein the one or more vectors further comprises:
a nucleic acid sequence encoding a first ligation sequence upstream of the effector molecule; and
a nucleic acid sequence encoding a second ligation sequence downstream of the effector molecule.

### Claim 36 (depends on 35)

The method of claim 35, wherein the nucleic acid sequence encoding the effector molecule is positioned downstream of the nucleic acid sequence encoding the first ligation sequence and upstream of the nucleic acid sequence encoding the second ligation sequence to produce a vector encoding the effector molecule.

### Claim 37 (depends on 35)

A treatment method comprising:
contacting a cell with a RNA molecule according to claim 35 under conditions effective to express of the effector molecule to treat the cell.

### Claim 38 (depends on 21)

A treatment method comprising:
contacting a cell with a vector according to claim 21 under conditions effective to express of the effector molecule to treat the cell.

### Claim 39

An RNA molecule comprising a 5′-OH end and a 2′,3′-cyclic phosphate end, wherein the RNA molecule further comprises an effector molecule between the 5′-OH and the 2′,3′-cyclic phosphate ends.

### Claim 40 (depends on 39)

The RNA molecule according to claim 39 further comprising a first ligation sequence upstream of the effector molecule and a second ligation sequence downstream of the effector molecule.
